Context

Atrial fibrillation (AF) is an established risk factor for stroke, and anticoagulation treatment is effective in reducing recurrent stroke risk. Guidelines recommend the use of clinical prediction tools to select patients with AF for anticoagulation therapy. It has long been recognised that paroxysmal AF (PAF) may pose a similar stroke risk to persistent AF, but the association between the duration of PAF and stroke risk remains uncertain. The best method to detect PAF has yet to be conclusively determined.1 ,2 This randomised controlled trial examines whether prolonged, non-invasive cardiac monitoring poststroke is superior to guideline-based standard treatment in PAF detection.